Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which focused on the development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. It is engaged in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and have exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson's disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of the major depressive disorder (MDD). Roluperidone is a compound that blocks serotonin, sigma, and a-adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson's disease and for other neurodegenerative disorders.

Employees

Sector

Biotechnology & Medical Research

Calendar

03/11/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
20/09/24	2.770 $	-1.65%	1,222
19/09/24	2.817 $	-1.17%	6,763
18/09/24	2.850 $	-2.06%	5,802
17/09/24	2.910 $	-0.51%	9,735
16/09/24	2.925 $	-0.85%	17,275

Delayed Quote Nasdaq, September 20, 2024 at 02:36 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2.817USD

Average target price

5.000USD

Spread / Average Target

+77.52%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Delayed Nasdaq Other stock markets 14:36:32 20/09/2024 BST			5-day change	1st Jan Change
2.770 ^USD	-1.65%		-6.10%	-54.96%

08-06	Minerva Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
05-30	Minerva Neurosciences, Inc. Announces Board Changes, Effective from August 6, 2024	CI

Capitalization	19.7M 1.48B	P/E ratio 2024 *	-1.32x	P/E ratio 2025 *	-1.39x
Enterprise value	43.01M 3.24B	EV / Sales 2024 *	0.98x	EV / Sales 2025 *	-
Free-Float	77.74%	Yield 2024 *	-	Yield 2025 *	-

Minerva Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-06	CI
Minerva Neurosciences, Inc. Announces Board Changes, Effective from August 6, 2024	05-30	CI
Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-01	CI
Sector Update: Health Care Stocks Ease Late Afternoon	02-27	MT
Top Midday Decliners	02-27	MT
Sector Update: Health Care Stocks Decline Tuesday Afternoon	02-27	MT
Minerva Neurosciences Shares Tumble After FDA Rejects Roluperidone for Schizophrenia.	02-27	MT
Minerva Neurosciences Shares Slide on Latest FDA Roluperidone Setback	02-27	DJ
FDA Turns Away Minerva's Roluperidone Schizophrenia Drug	02-27	DJ
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia	02-27	CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-22	CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI

HC Wainwright Adjusts Price Target on Minerva Neurosciences to $11 From $8, Maintains Neutral Rating	02/08/23	MT
HC Wainwright Downgrades Minerva Neurosciences to Neutral From Buy	10/11/22	MT
JMP Securities Downgrades Minerva Neurosciences to Market Perform From Outperform, Removes $21 Price Target	17/10/22	MT
HC Wainwright Adjusts Price Target on Minerva Neurosciences to $24 From $40, Reiterates Buy Rating	23/08/22	MT
HC Wainwright Adjusts Minerva Neurosciences' Price Target to $5 from $10, Keeps Buy Rating	04/03/22	MT

Minerva Neurosciences, Inc. Share Price

Equities

NERV

US6033802058

Biotechnology & Medical Research

Valuation: Minerva Neurosciences, Inc.

Chart: Minerva Neurosciences, Inc.

Latest news: Minerva Neurosciences, Inc.

Analysts' recommendations: Minerva Neurosciences, Inc.

Press Releases: Minerva Neurosciences, Inc.

News in other languages: Minerva Neurosciences, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Minerva Neurosciences, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly earnings, Rate of surprise

Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates	08-07	AQ
Minerva Neurosciences: Q2 Earnings Snapshot	08-06	AQ
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates	08-06	AQ
Minerva Neurosciences: Q1 Earnings Snapshot	05-01	AQ
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates	05-01	AQ

Wall Street finit en baisse pour la 5e séance d'affilée	06/01/15
AOL : Léger rebond à Wall Street à l'ouverture après la chute de lundi	06/01/15
AOL : Les valeurs à suivre à Wall Street	06/01/15

1 day	-1.65%
1 week	-6.10%
Current month	+1.09%
1 month	+4.14%
3 months	-19.48%
6 months	+2.59%
Current year	-54.96%

Director	Title	Age	Since
Rémy Henri Luthringer CEO	Chief Executive Officer	63	28/02/14
Geoff Race FOU	Founder	63	30/06/10
Fred Ahlholm DFI	Director of Finance/CFO	58	31/12/13

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
MINERVA NEUROSCIENCES, INC.	-1.65%	-6.10%	-64.98%	-80.76%	19.7M
REGENERON PHARMACEUTICALS, INC.	-0.61%	-0.80%	+37.58%	+78.52%	124B
VERTEX PHARMACEUTICALS INCORPORATED	-0.86%	-2.29%	+34.61%	+155.43%	123B
ARGENX SE	-0.44%	-1.66%	-1.58%	+73.56%	32.12B
BIONTECH SE	+0.84%	-8.12%	+4.39%	-66.56%	26.75B
BEIGENE, LTD.	+4.00%	+4.29%	+7.35%	-48.05%	21.11B
SUMMIT THERAPEUTICS INC.	+3.37%	-25.46%	+1,179.54%	+273.03%	17.02B
GENMAB A/S	-2.35%	-4.36%	-34.29%	-37.17%	16.74B
WUXI APPTEC CO., LTD.	+1.65%	+2.31%	-49.40%	-73.31%	16.4B
VAXCYTE, INC.	+0.80%	+0.99%	+132.66%	+357.78%	14.49B
Average	+0.42%	+0.15%	+124.59%	+63.25%	39.21B
Weighted average by Cap.	-0.11%	-0.01%	+75.91%	+93.06%

	2024 *	2025 *
Net sales	20M 1.51B	-
Net income	-12.94M -974M	-29.52M -2.22B
Net Debt	-	-

Manager	Title	Age	Since
Rémy Henri Luthringer CEO	Chief Executive Officer	63	28/02/14
Jan van Heek BRD	Director/Board Member	75	30/06/14
Fouzia Laghrissi-Thodes BRD	Director/Board Member	61	17/05/15